Latest

2 stories

Hide weekly roundups

Thursday, August 13

Grace Therapeutics details GTx-104 resubmission plan after CRL, sets cash runway to 2028

Grace Therapeutics said its FDA rejection cited manufacturing and non-clinical issues, not safety or efficacy, as it pursues a two-site production strategy.

SEC filing

Monday, August 10

FinancingGrace Therapeutics Inc.

Grace Therapeutics raises $10 million in private placement for GTx-104

The Princeton biopharma will use the proceeds for manufacturing and regulatory work on its nimodipine infusion candidate, with a Form D confirming nine investors participated.

SEC filing (2)